Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

Blood - Tập 98 - Trang 2269-2271 - 2001
Carina Seidel1,2,3,4, Øyvind Hjertner1,2,3,4, Niels Abildgaard1,2,3,4, Lene Heickendorff1,2,3,4, Martin Hjorth1,2,3,4, Jan Westin1,2,3,4, Johan Lanng Nielsen1,2,3,4, Henrik Hjorth-Hansen1,2,3,4, Anders Waage1,2,3,4, Anders Sundan1,2,3,4, Magne Børset1,2,3,4
1From the Institute of Cancer Research and Molecular Biology, and the Section of Hematology, Department of Internal Medicine, University Hospital, Norwegian University of Science and Technology, Trondheim, Norway;
2the Department of Hematology, Lund University Hospital, Lund, Sweden;
3the Department of Medicine, Lidköping Hospital, Lidköping, Sweden;
4and the Department of Hematology and Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Tóm tắt

Osteoprotegerin (OPG), the neutralizing decoy receptor for the osteoclast activator RANK ligand, was measured in serum taken from patients with multiple myeloma at the time of diagnosis. Median OPG was lower in the patients with myeloma (7.4 ng/mL; range, 2.6-80; n = 225) than in healthy age- and sex-matched controls (9.0 ng/mL; range 5.1-130; n = 40; P = .02). Importantly, OPG levels were associated with degree of radiographically assessed skeletal destruction (P = .01). The median OPG level in patients lacking osteolytic lesions was 9.1 ng/mL, as compared with 7.6 ng/mL and 7.0 ng/mL, respectively, in patients with minor or advanced osteolytic disease. Furthermore, OPG levels were associated with World Health Organization performance status (P = .003) and correlated to serum levels of carboxy-terminal propeptide of type I procollagen (PICP; P < .001) but not with clinical stage or survival. These findings suggest impaired OPG function in myeloma and give a rationale for OPG as a therapeutic agent against myeloma bone disease.

Tài liệu tham khảo

Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation., Cell., 93, 165, 10.1016/S0092-8674(00)81569-X Hofbauer, 2000, The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption., J Bone Miner Res., 15, 2, 10.1359/jbmr.2000.15.1.2 The Nordic Myeloma Study Group, 1996, Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial., Ann Intern Med., 124, 212, 10.7326/0003-4819-124-2-199601150-00004 Durie, 1975, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival., Cancer., 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U Turesson, 1999, Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors., Br J Haematol., 106, 1005, 10.1046/j.1365-2141.1999.01651.x Seidel, 2000, Serum syndecan-1: a new independent prognostic marker in multiple myeloma., Blood., 95, 388, 10.1182/blood.V95.2.388 Abildgaard, 1997, Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal propeptide of type I collagen (ICTP)., Br J Haematol., 96, 103, 10.1046/j.1365-2141.1997.8672495.x Mundy, 1974, Evidence for the secretion of an osteoclast stimulating factor in myeloma., N Engl J Med., 291, 1041, 10.1056/NEJM197411142912001 Hjertner, 1999, Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease., Blood., 94, 3883, 10.1182/blood.V94.11.3883 Michigami, 2000, Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity., Blood., 96, 1953, 10.1182/blood.V96.5.1953 Bataille, 1991, Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma., J Clin Invest., 88, 62, 10.1172/JCI115305 Udagawa, 2000, Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function., Endocrinology., 141, 3478, 10.1210/endo.141.9.7634 Yano, 1999, Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis., J Bone Miner Res., 14, 518, 10.1359/jbmr.1999.14.4.518 Borset, 2000, Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins., Blood., 96, 2528, 10.1182/blood.V96.7.2528 Fuki, 1997, The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro., J Clin Invest., 100, 1611, 10.1172/JCI119685 Fuki, 2000, Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts., Biochem J., 351, 607, 10.1042/bj3510607 Bataille, 1989, Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease., J Clin Oncol., 7, 1909, 10.1200/JCO.1989.7.12.1909 Risteli, 1993, Biochemical markers of bone metabolism., Ann Med., 25, 385, 10.3109/07853899309147301 Abildgaard, 2000, Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma., Eur J Haematol., 64, 121, 10.1034/j.1600-0609.2000.90074.x Honore, 2000, Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord., Nat Med., 6, 521, 10.1038/74999
Thông tin
Thông tin xuất bản

Blood

Tập 98

2269-2271

Thông tin tác giả